Technical Analysis for CKPT - Checkpoint Therapeutics, Inc.
|Grade||Last Price||% Change||Price Change|
CKPT closed down 4.66 percent on Monday, December 10, 2018, on 37 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
|Weak or Absent||Down||Down||Down|
|See historical CKPT trend table...|
|Date||Alert Name||Type||% Chg|
|Dec 10||Narrow Range Bar||Range Contraction||0.00%|
|Dec 10||NR7||Range Contraction||0.00%|
|Dec 10||NR7-2||Range Contraction||0.00%|
|Dec 10||Down 3 Days in a Row||Weakness||0.00%|
|Dec 10||Down 4 Days in a Row||Weakness||0.00%|
|Dec 10||Down 5 Days in a Row||Weakness||0.00%|
|Dec 7||20 DMA Resistance||Bearish||-4.66%|
|Dec 7||NR7||Range Contraction||-4.66%|
|Dec 7||Inside Day||Range Contraction||-4.66%|
|Dec 7||Down 3 Days in a Row||Weakness||-4.66%|
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
Checkpoint Therapeutics, Inc. is an immuno-oncology biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. The Company is engaged in developing a portfolio of human immuno-oncology targeted antibodies. The portfolio of antibodies that it licensed includes antibodies targeting programmed death-ligand 1 (PD-L1), glucocorticoid-induced Tumor necrosis factor receptor (TNFR) related protein (GITR) and carbonic anhydrase IX (CAIX). It focuses on developing the immuno-oncology and checkpoint inhibitor antibodies. It is developing three oral, small molecules, targeted anti-cancer agents, consisting of an inhibitor of epidermal growth factor receptor (EGFR) mutations, an inhibitor of the bromodomain and extra-terminal (BET) protein, BRD4, and an inhibitor of poly (ADP-ribose) polymerase (PARP). Its pipeline of products includes CK-101 and CK-103.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more CKPT news...
|52 Week High||6.29|
|52 Week Low||1.89|
|200-Day Moving Average||3.3875|
|50-Day Moving Average||2.5586|
|20-Day Moving Average||2.296|
|10-Day Moving Average||2.304|
|Average True Range||0.2969|
|Chandelier Exit (Long, 3 ATRs )||1.9993|
|Chandelier Exit (Short, 3 ATRs )||2.7807|
|Upper Bollinger Band||2.5567|
|Lower Bollinger Band||2.0353|
|Percent B (%b)||0.22|
|MACD Signal Line||-0.0965|
|Market Cap||54.54 Million|
|Num Shares||25.4 Million|
|Price-to-Earnings (P/E) Ratio||-1.95|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||2.30|
|Resistance 3 (R3)||2.31||2.26||2.28|
|Resistance 2 (R2)||2.26||2.23||2.26||2.27|
|Resistance 1 (R1)||2.21||2.20||2.19||2.20||2.26|
|Support 1 (S1)||2.11||2.13||2.09||2.10||2.04|
|Support 2 (S2)||2.06||2.10||2.06||2.03|
|Support 3 (S3)||2.01||2.06||2.03|
|Support 4 (S4)||2.00|